

# Antibe Therapeutics, Inc.

18:30 25 Jun 2019

## Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Antibe Therapeutics Inc (CVE:ATE) (OTCMKTS:ATBPF) released a shareholder update Tuesday, including highlights about the company's Phase 2 development for its flagship ATB-346 drug, as the firm launches into global partnering discussions.

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track.

It's been a pivotal year for the company, which launched its head-to-head Phase 2B study versus naproxen, the most prescribed NSAID in the United States.

**READ:** Antibe Therapeutics CEO Dan Legault on why the multibillion-dollar NSAID market needs disruption

"Our overarching objective for shareholders remains the same: monetize our drug pipeline through high-value partnerships for the large pharmaceutical markets," said CEO Dan Legault in a statement. "Given the strength of our existing data package and the successful conclusion of Phase 2 within our reach, we feel we are well positioned to deliver upon that goal."

The company's Phase 2B efficacy study has a total of 360 patients across 35 clinical sites, in "one of the largest clinical studies ever undertaken in Canada," noted the firm. The company says a successful trial will validate the best-in-class status of the drug in a US\$11 billion drug category and could set the stage for global partnering activity.

The study is designed to validate the effectiveness of ATB-346 in reducing osteoarthritis pain and establish the lowest effective dose.

"Importantly, this is the final Phase 2 study for ATB-346 and represents a major development milestone and inflection point for Antibe if one of the doses meets the primary endpoint," said Legault.

### Gearing up for FDA meeting

Antibe is also working on getting the drug ready for an investigational new drug (IND) application, as well as a end-of-Phase-2 meeting with the FDA. The preparation is intense, requiring comprehensive data packages encompassing pharmacokinetics, metabolism, toxicology, chemistry and manufacturing, among other factors.

The company has assembled a team of regulatory experts to support the initiative, including several former heads of FDA directorates and a regulatory agency based out of Washington, DC.

**READ:** Antibe Therapeutics is poised to disrupt the global pain management industry

The company also noted it has seen mounting interest in ATB-346 and is in discussions with a number of pharmaceutical companies.

**Price:** 0.425

**Market Cap:** \$116.52 m

### 1 Year Share Price Graph



### Share Information

**Code:** ATE

**Listing:** TSX-V

52 week	High	Low
	0.54	0.235

**Sector:** Pharma & Biotech

**Website:** antibethera.com

### Company Synopsis:

*Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a \$20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention.*

action@proactiveinvestors.com

"Assuming the Phase 2B efficacy results are favourable, we anticipate being in a position of strength to execute a series of regional and global licensing deals," said Legault.

#### Also pushing forward its non-opioid acute painkiller

In addition to its lead drug, ATB-346, the firm also continues to leverage its hydrogen sulfide (H<sub>2</sub>S) technology platform and work on the next drug in its pipeline, ATB-352, a non-addictive, potent analgesic for treating acute pain. ATB 352 is a derivative of ketoprofen, a potent NSAID for acute pain. Its intended use will be in competition with strong opioids such as fentanyl and oxycontin.

"Post-operative pain is a US\$9 billion market opportunity that is in desperate need of safer treatment alternatives without abuse potential," said Legault. "Furthermore, the recent characterization of our strategy for ATB-352 affirms to potential partners that Antibe is building a best-in-class platform of drug candidates that address several blockbuster markets."

#### Regenerative medicine asset delivering impressive growth

The company also noted Citagenix Inc., its commercial asset in regenerative medicine, is seeing strong growth as it continues its US expansion.

Sales in the United States were up 62% year-over-year in fiscal 2019 and the company says it is seeing the growth rate accelerate currently.

"We expect its recent performance to benefit strategic discussions that are geared to unlock additional value for shareholders," said Legault.

Shares of Antibe Therapeutics were up 3.1% at C\$0.33 in Toronto, up 5% at US\$0.25 in New York on Tuesday.

Contact Katie Lewis at [katie@proactiveinvestors.com](mailto:katie@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

#### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics, Inc. named herein, including the promotion by the Company of Antibe Therapeutics, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).